Drugs / JS203
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05618327 | Feb 2023 → Dec 2026 expected | B-cell non-Hodgkin lymphoma | Shanghai Junshi Bioscience Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07081022 | Aug 2025 → Apr 2027 expected | B-cell non-Hodgkin lymphoma | Shanghai Junshi Bioscience Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JS203 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07081022 ↗ |